Literature DB >> 366484

Vaginal flora in women undergoing hysterectomy with antibiotic prophylaxis.

J H Grossman, R L Adams.   

Abstract

One objection occasionally raised against the use of routine antibiotic prophylaxis for pelvic surgery is the concern that the flora of treated patients will be altered, thus favoring the emergence of different, potentially more resistant organisms. This report summarizes experience with 100 women undergoing elective hysterectomy who were subjected to short-term cefazolin, penicillin, or placebo prophylaxis. The changes in preoperative versus postoperative flora were similar among antibiotic-treated and placebo-treated groups. In general, postoperative isolation of gram-negative aerobes and Bacteroides sp increased, and isolation of gram-positive aerobes (except group D streptococci) decreased in antibiotic-treated and placebo-treated groups. The clinical implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 366484

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Prophylactic perioperative use of clindamycin and metronidazole in vaginal hysterectomy without pelvic floor repair.

Authors:  C Egarter; R Fitz; R Brehm; P Husslein
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

2.  Methods for quantitative and qualitative evaluation of vaginal microflora during menstruation.

Authors:  A B Onderdonk; G R Zamarchi; J A Walsh; R D Mellor; A Muñoz; E H Kass
Journal:  Appl Environ Microbiol       Date:  1986-02       Impact factor: 4.792

3.  Association of viridans group streptococci from pregnant women with bacterial vaginosis and upper genital tract infection.

Authors:  L K Rabe; K K Winterscheid; S L Hillier
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

4.  Antibiotic-associated Vulvovaginal Candidiasis.

Authors:  Jinping Xu; Jack D. Sobel
Journal:  Curr Infect Dis Rep       Date:  2003-12       Impact factor: 3.725

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.